By: Christopher Parrella, Esq., CPC, CHC, CPCO
Parrella Health Law, Boston, Ma.
A Health Care Provider Defense and Compliance Firm

Eli Lilly, the pharmaceutical giant behind the popular weight-loss drug Zepbound, is taking a groundbreaking step by exploring its potential to treat alcohol and drug addiction. CEO David Ricks announced that the company will begin major clinical trials next year, marking the first time a major drugmaker has tested a weight-loss treatment for addiction therapy.

The Science Behind It

Zepbound is part of a class of medications based on the GLP-1 hormone, originally known for its role in controlling blood sugar and appetite. However, emerging research shows that these drugs also influence brain circuits responsible for cravings—not just for food, but possibly for alcohol, nicotine, and other addictive substances.

“These medicines… reduce that desire cycle,” Ricks explained at a recent event hosted by The Economic Club of Washington D.C. “Next year, you’ll see Lilly start large studies in alcohol abuse, nicotine use, even in drug abuse.”

What Makes This a Game-Changer?

Preliminary studies have linked GLP-1 drugs to reduced rates of substance use disorder. Nora Volkow, director of the National Institute on Drug Abuse, called the data “very, very exciting.” While Lilly’s competitor, Novo Nordisk, is also researching similar drugs, Lilly is the first to focus directly on addiction treatment.

Looking Ahead: Easier Access?

Ricks also mentioned that Eli Lilly is working on an oral version of the drug, which could make it easier to distribute—potentially paving the way for over-the-counter access in the future. However, the company will need more safety data before pursuing that path.

Why It Matters

This bold move could change how addiction is treated, offering a new avenue of hope for millions battling substance use disorders. If successful, these studies could reshape the addiction treatment landscape and bring life-saving therapies to more people.

Need Legal Guidance in Healthcare Innovation?

Parrella Health Law specializes in healthcare compliance and regulatory issues for life sciences and pharmaceutical companies. If your organization is navigating clinical trials, FDA approvals, or health law compliance, our team can help. Contact Parrella Health Law at 857.328.0382 or email Chris directly at cparrella@parrellahealthlaw.com.